Pulsed proton beams aim to tame tough pancreatic tumors
NCT ID NCT07269626
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a new radiation technique called PULSAR, which delivers short, powerful proton beam pulses every few weeks, adapted to tumor changes. It is for people with locally advanced or limited metastatic pancreatic cancer who have already had some chemotherapy. The goal is to improve local control and survival while reducing damage to nearby organs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Proton beam radiation delivered in personalized ultra-fractionated pulses (PULSAR)
- What this could lead to
- If successful, this approach could improve local tumor control and survival for patients with advanced pancreatic cancer while reducing side effects from radiation.
- What could go wrong
- This is a small, early-phase (phase II) trial with only 47 participants, so results may not apply broadly. The combination therapy may still cause toxicity or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Select Province/State, 06351, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene test may guide smarter chemo for pancreatic cancer
- Could a special MRI help doctors better treat pancreatic cancer?
- Triple attack on pancreatic cancer: radiotherapy, chemo, and immunotherapy aim to make tumors removable
- Triple threat against pancreatic cancer: radiation, immunotherapy, and chemotherapy combined
- Experimental combo therapy targets Hard-to-Treat pancreatic cancer
- Promising cocktail may shrink pancreatic tumors before surgery